Navigation Links
Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
Date:3/11/2008

rms of heart disease."

About Corgentin

Cardium's Corgentin (Ad5IGF-I) preclinical product candidate is a next-generation DNA-based therapeutic using the insulin-like growth factor-I gene carried by an adenovector that is being developed as a potential one-time treatment to promote the preservation and restoration of heart tissue and cardiac function following a heart attack (acute myocardial infarction). Cardium believes that Corgentin, which effectively enables prolonged IGF-I expression within the heart muscle, offers the potential to prevent further damage to heart muscle and improve cardiac healing following a heart attack. The inherent biological properties of IGF-I, which include inhibition of cardiomyocyte apoptosis, adaptive cardiomyocyte hypertrophy, recruitment of cardiac progenitor cells, as well as the induction of angiogenesis and enhancement of cardiac function, combined with Cardium's delivery approach to yield sustained localized expression, provide the rationale for the development of a therapy directed at myocardial repair and restoration. This combination of positive biological attributes and effective delivery supports the potential of Corgentin to improve functional recovery and prevent ventricular dysfunction and the associated progression to congestive heart failure following myocardial infarction and reperfusion.

According to the American Heart Association, the estimated annual incidence of myocardial infarction (MI) is 600,000 new attacks and 320,000 recurrent attacks. Even with the best of care and successful early intervention, such as tissue plasminogen activator (tPA) or emergency angioplasty, about 30% of heart attack patients will eventually go on to develop decompensation through ventricular remodeling and progressive congestive heart failure. This explains in large part why heart failure remains an epidemic health problem despite improved treatments for acute cardiac events.

The safety of systemic IGF-I pr
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Genmab Announces Encouraging Preclinical Data for ofatumumab
2. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
3. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
4. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
5. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
6. Arpida Presents Preclinical Data on AR-2474 at ICAAC
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
9. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
10. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
11. GelVac(TM) Nasal Powder H5N1 (Bird Flu) Influenza Vaccine Passes Preclinical Toxicology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)...  Indianapolis-based medical device manufacturer NICO Corporation is ... products including the BrainPath® and Myriad™ technologies offering ... abnormalities and then removing affected tissue. More than ... 50 institutions throughout the United States ... in 12 abstracts, three peer-reviewed publications, and seven ...
(Date:5/4/2015)... , May 4, 2015 Tobira Therapeutics, ... on the development and commercialization of novel treatments ... completion of its merger with Regado Biosciences, Inc. ... the closing of the merger, Tobira raised $40 ... new investors and all current Tobira institutional investors, ...
(Date:5/4/2015)... AVIV, Israel , May 4, 2015  Tikcro ... filed its annual report on Form 20-F for the ... Securities and Exchange Commission ("SEC"). The annual report on ... the development of antibodies in the area of cancer ... with superior qualities of high specificity and binding in ...
(Date:5/4/2015)... , May 4, 2015  RegeneRx Biopharmaceuticals, ... announced that an independent team of researchers from ... that Thymosin B4 (TB4) plays an important role ... wounds, induced in an experimental mouse model, by ... remodeling of damaged dermal tissue.  The research found ...
Breaking Biology Technology:NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 2Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 3
... 29 Nastech,Pharmaceutical Company Inc. (Nasdaq: NSTK ... nine-month periods ended September 30, 2007. Revenue ... $1.9 million,compared to $5.5 million for the quarter ... of $4.8 million related to our Parathyroid Hormone,(PTH1-34) ...
... Oct. 29 /PRNewswire/ - N30 Pharma (N30), a,biopharmaceutical ... respiratory drugs that target endogenous,s-nitrosothiols, today announced a ... covering the respiratory use of a s-nitrosothiol drug,candidate. ... "I am extremely pleased to announce this ...
... LA JOLLA, Calif., Oct. 29 TorreyPines Therapeutics,Inc. (Nasdaq: ... President and,Chief Executive Officer of TorreyPines, will present at ... in New York on Monday,November 5th at 9:10 a.m., ... be available live. You can,access the webcast at: ...
Cached Biology Technology:Nastech Announces Third Quarter 2007 Financial Results 2Nastech Announces Third Quarter 2007 Financial Results 3Nastech Announces Third Quarter 2007 Financial Results 4Nastech Announces Third Quarter 2007 Financial Results 5Nastech Announces Third Quarter 2007 Financial Results 6
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... the "Global Gesture Recognition Market in Automotive Sector ... analysts forecast the Global Gesture Recognition market in Automotive ... the period 2013-2018. Gesture recognition is the ... different gestures of an individual. Gesture recognition technology can ...
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... grains with solubles (DDGS) to growing pigs, many questions are ... "Previous research shows that while the amount of energy ... lower digestibility of energy in DDGS than in corn," said ... Department of Animal Sciences. "Our goal was to find out ...
... University of Pennsylvania biologists studying human reproduction ... factor to the maternal age-associated increase in aneuploidy, ... during reproductive cell division. Using naturally aging ... of reproductive life is most likely caused by ...
... who develop life-threatening bacterial infections, or septicemia, with insulin ... infection, if results of a new preliminary study can ... online ahead of print in Diabetes Care ... oxidative stress in study participants who had been injected ...
Cached Biology News:Swine researchers seek answers to fiber's low digestibility 2Why the biological clock? Penn study says aging reduces centromere cohesion, disrupts reproduction 2Insulin may reduce several inflammatory factors induced by bacterial infection 2
... Introduction of a protein into cells permits ... signaling pathways, apoptotic pathways, and transcription factor-mediated ... studying the effects of a specific protein ... the protein directly into the cell. ProteoJuice ...
... SE flow cytometry system is the superior ... over 25 years, BD cell sorters have ... in leading university, pharmaceutical, and biotechnology research ... the research demands of today, we have ...
... is a microarray service provider ... academic researchers. We are a ... and we provide expression profiling ... arrays. Gene expression reports ...
... Control and regulate cell stretching or compression ... microscope stage. Computer controlled so you can ... the strain to produce 64 unique strain ... then the ST-150. Both models are compatible ...
Biology Products: